Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 3, 1998, Pages 249-254

  Lin, Nan Horng ^a   Gunn, David E ^a   Li, Yihong ^a   He, Yun ^a   Bai, Hao ^a   Ryther, Keith B ^a   Kuntzweiler, Theresa ^a   Donnelly Roberts, Diana L ^a   Anderson, David J ^a   Campbell, Jeffrey E ^a   Sullivan, James P ^a   Arneric, Stephen P ^a   Holladay, Mark W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (PYRROLIDINYL)METHOXY]PYRIDINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CHEMICAL MODIFICATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; STRUCTURE ACTIVITY RELATION;

CELL LINE; HUMANS; ION TRANSPORT; NICOTINIC AGONISTS; PYRIDINES; PYRROLIDINES; RUBIDIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0032477904     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00019-5     Document Type: Article

References (15)

1. 1. Holladay, M. W.; Lebold, S. A.; Lin, N.-H. Drug Devel. Res. 1995, 35, 191-213.
2. 2. Arneric, S. P.; Sullivan, J. P.; Williams, M. In Psychopharmacology: Fourth Generation of Progress; Bloom, E. B.; Kuper, D. J. Eds.; Raven: New York, 1995; pp 95-110.
3. 3. Meyer, E. M.; de Fiebre, C. M.; Hunter, B. E.; Simpkins, C. E.; Frauworth, N.; de Fiebre, N. E. C. Drug Devel. Res. 1994, 31, 127-134.
4. 4. Garvey, D. S.; Wasicak, J. T.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Sullivan, J. P.; Carrera, G. M.; Holladay, M. W.; Arneric, S. P.; Williams, M. J. Med. Chem. 1994, 37, 1055-1059.
5. 5. Abreo, M. A.; Lin, N.-H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A.-M.; Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly-Roberts, D. L.; Anderson, D. J.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. J. Med. Chem. 1996, 39, 817-825.
6. 6. Lin, N.-H.; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M.; Brioni, J. D.; Buckley, M. J.; Rodrigues, D.; Marsh, K.; Anderson, D. J.; Buccafusco, J. J.; Prendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. J. Med. Chem. 1997, 40, 385-390.
7. 7. McBride, P. E. Med. Clin. N. Am. 1992, 76, 333-353.
8. 8. Carlson, G. M.; Ruddon, R. W.; Hug, C. C., Jr.; Schmiege, S. K.; Bass, P. J. Pharmacol. Exp. Ther. 1970, 173, 377-383.
9. 9. Snieckus, V. Heterocyde 1980, 14, 1649.
10. 10. Moore, J. A.; Marasia, F. J. J. Am. Chem. Soc. 1959, 81, 6049-6055.
11. 11. Effenberger, F.; Krebs, A.; Willrett, P. Z. Chem. Ber. 1992, 125, 1131-1140.
12. 12. Vozza, J. F. J. Org. Chem. 1962, 27, 3856.
13. 13. Wozniak, M.; Baranski, A.; Szpakiewicz, B. Liebigs Ann. Chem. 1993, 1, 7-10.
14. 14. Tamao, K.; Kodama, S.; Nakajima, I.; Kumada, M. Tetrahedron 1982, 22, 3347-3353.
15. 15. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. Mol. Pharm. 1991, 41, 31-37.